Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Date of Report: July 31, 2026
Event: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard (Item 3.01).
Key Financial Metrics
This filing is a current report regarding listing status and does not contain financial statements. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Listing Status
- Trigger Event: The bid price for Humacyte's common stock closed below the minimum $1.00 per share requirement for 30 consecutive business days ended July 30, 2026.
- Regulatory Action: Nasdaq notified the Company of non-compliance with Listing Rule 5450(a)(1).
- Compliance Period: The Company has been granted an initial 180-calendar day period to regain compliance, ending January 27, 2027.
- Compliance Requirement: The closing bid price must be $1.00 or more for a minimum of 10 consecutive business days prior to the deadline.
- Current Status: The stock continues to trade on The Nasdaq Global Select Market under the symbol "HUMA" with no immediate effect on operations or reporting obligations.
Outlook, Risks, and Management Commentary
Management intends to monitor the bid price and consider available options to achieve compliance. However, the Company explicitly states there can be no assurance that it will regain compliance during the allotted period. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to economic, business, competitive, and reputational factors. Risks include the potential for delisting if compliance is not met and uncertainties regarding future liquidity and trading of securities.
Investor Verification Checklist
- Verify the current closing bid price of HUMA stock relative to the $1.00 threshold.
- Monitor the stock price for 10 consecutive business days to assess progress toward the January 27, 2027 deadline.
- Review the Company's most recent Form 10-K (year ended Dec 31, 2025) and Form 10-Q (quarter ended March 31, 2026) for detailed financial health and risk factors.
- Watch for subsequent 8-K filings regarding potential reverse stock splits or other corporate actions intended to restore compliance.